Sally, A., Nasser, M., Mahmoud, A., Raghda, F., Amany, H., Reham, S. (2018). Recent trends in chronic hepatitis C virus treatment. Medical Journal of Viral Hepatitis, 2.2(2), 1-6. doi: 10.21608/mjvh.2018.55734
abed Sally; Mousa Nasser; Abdel-Aziz Mahmoud; Farag Raghda; Hasson Amany; Soliman Reham. "Recent trends in chronic hepatitis C virus treatment". Medical Journal of Viral Hepatitis, 2.2, 2, 2018, 1-6. doi: 10.21608/mjvh.2018.55734
Sally, A., Nasser, M., Mahmoud, A., Raghda, F., Amany, H., Reham, S. (2018). 'Recent trends in chronic hepatitis C virus treatment', Medical Journal of Viral Hepatitis, 2.2(2), pp. 1-6. doi: 10.21608/mjvh.2018.55734
Sally, A., Nasser, M., Mahmoud, A., Raghda, F., Amany, H., Reham, S. Recent trends in chronic hepatitis C virus treatment. Medical Journal of Viral Hepatitis, 2018; 2.2(2): 1-6. doi: 10.21608/mjvh.2018.55734
Recent trends in chronic hepatitis C virus treatment
2Tropical Medicine dept., Port Said, Univ., Egypt. & Egyptian Liver Research Institute and Hospital (ELRIH), Sherbin, Mansoura
Abstract
Hepatitis The hepatitis C virus is the major cause of progressive liver diseases and a public health problem worldwide. At present, hepatitis C has become a curable disease with the use of new interferon-free regimens based on direct-Acting Antiviral agents (DAA.s). Direct-acting antivirals directly target the viral protease, polymerase, or non-structural proteins. These agents have been approved by FDA in various combinations to interrupt HCV replication at different sites. The introduction of DAAs has increased the number of patients who respond to treatment, and has changed radically the treatment of chronic HCV with reported sustained virologic response (SVR) rates exceeding 95% in treating patients. Treatment for chronic HCV is based on guidelines from the Infectious Diseases Society of America (IDSA) and the American Associations for the Study of Liver Diseases (AASLD), in collaboration with the International Antiviral Society-USA (IAS-USA). Based on available resources, patients at high risk for liver-related complications and severe extrahepatic hepatitis C complications should be given high priority for treatment. This article aims to summarize newly available treatment regimens and special considerations for each regimen, such as coinfection with human immunodeficiency virus (HIV), compensated or decompensated cirrhosis, and Post-transplant patients.
View on SCiNiTO
Top